Ameriprise Financial Inc Aveo Pharmaceuticals, Inc. Transaction History

Ameriprise Financial Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$8.48 - $14.97 $1 Million - $1.77 Million	-117,987 Reduced 74.35%	40,705 $608,000
Q3 2022 Nov 14, 2022	SELL	$6.61 - $8.72 $24,509 - $32,333	-3,708 Reduced 2.28%	158,692 $1.31 Million
Q2 2022 Aug 15, 2022	BUY	$3.51 - $6.67 $570,024 - $1.08 Million	162,400 New	162,400 $1.07 Million
Q4 2020 Feb 12, 2021	SELL	$5.08 - $6.68 $201,371 - $264,795	-39,640 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$4.16 - $6.26 $164,902 - $248,146	39,640 New	39,640 $235,000

Ticker AVEO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,676,000
Description
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the ...

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Ameriprise Financial Inc with notifications on news.